Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts)
Authors
Tay, RebeccaChiramel, Jaseela
Montague, E
Wilson, F
Summers, Yvonne J
Blackhall, Fiona H
Califano, Raffaele
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2018
Metadata
Show full item recordCitation
Tay RY, Chiramel J, Montague E, Wilson F, Summers Y, Blackhall FH, et al. 1462P Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol. 2018;29(suppl_8):529.Journal
Annals of OncologyDOI
10.1093/annonc/mdy292.084Additional Links
https://dx.doi.org/10.1093/annonc/mdy292.084Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy292.084